Skip To Main Content

Science at Sanofi

Discover a wide variety of articles, videos, podcasts, accredited courses, applications, conferences and scientific events in different therapeutic areas

Sort by

Filters

Reset
  • Therapeutical Areas
  • Type of Content
EVOLUTION: RWE from Saudi Arabia

EVOLUTION: RWE from Saudi Arabia

Evaluating the clinical effectiveness and safety of insulin glargine 300 U/ml in individuals with T2D uncontrolled on Basal insulin: A real-world evidence study form Saudi Arabia (EVOLUTION).

Treatment simplification of complex insulin regimens in T2D

Treatment simplification of complex insulin regimens in T2D

An educational video to discuss the challenges associated with commonly-used insulin advancement options and the need for treatment simplification for many adults with T2D. The video reviews data supporting the use of BI + GLP-1 RA FRCs versus commonly-used insulin regimens in adults with T2D.

Advancing Therapy with iGlarLixi: Differentiation from complex insulin regimens

Advancing Therapy with iGlarLixi: Differentiation from complex insulin regimens

An educational video outlining key data from indirect comparisons of iGlarLixi versus IDegAsp.

Advancing Therapy with iGlarLixi: Differentiation from other complex regimens

Advancing Therapy with iGlarLixi: Differentiation from other complex regimens

Real world Evidences

Real world Evidences

Advancing Therapy with iGlarLixi

Advancing Therapy with iGlarLixi

Treatment simplification in T2D: A less-is-more approach to help reduce the burden of disease

Treatment simplification in T2D: A less-is-more approach to help reduce the burden of disease

Treatment simplification for adults with Type 2 diabetes

Treatment simplification for adults with Type 2 diabetes

Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)

Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)

Watch the video tackling the critical topic of dyslipidemia management post-acute coronary syndrome. Globally, despite its pivotal role in secondary prevention, the approach remains suboptimal, so we'll dissect Arafah MR et al recent publication, providing a detailed evaluation of lipid management after ACS in Saudi Arabia. Specifically, shining a spotlight on LDL-cholesterol management and delve into the complications of statin use in post-ACS Saudi patients.

Management of Patients With Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: 1-year Outcomes of The PERI-DYS Study

Management of Patients With Very High Cardiovascular Risk Eligible for PCSK9 Inhibitor Treatment: 1-year Outcomes of The PERI-DYS Study

Prospective evaluation of lipid management following acute coronary syndrome in Saudi Arabia

Prospective evaluation of lipid management following acute coronary syndrome in Saudi Arabia

Hypercholesterolemia Treatment Patterns and Lipid Target in ACS Patients: HYDRA-ACS Registry

Hypercholesterolemia Treatment Patterns and Lipid Target in ACS Patients: HYDRA-ACS Registry